Ex-lax Pill
NDC Package 0067-8142-01
Package Information
Ex-lax (sennosides) pills is sennosides are used to treat constipation. This formulation utilizes a pill delivery system. Marketed by Haleon Us Holdings Llc, this product is identified by NDC 0067-8142 and is authorized under FDA application M007.
Identification & Billing
- RxCUI: 213073 - Ex-Lax Maximum Strength 25 MG Oral Tablet
- RxCUI: 213073 - sennosides, USP 25 MG Oral Tablet [Ex-Lax Maximum Relief Formula]
- RxCUI: 213073 - Ex-Lax Maximum Relief Formula 25 MG Oral Tablet
- RxCUI: 251292 - sennosides 25 MG Oral Tablet
- RxCUI: 251292 - sennosides, USP 25 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0067 - Haleon Us Holdings Llc
- 0067-8142 - Ex-lax
- 0067-8142-01 - 2 BLISTER PACK in 1 CARTON / 12 PILL in 1 BLISTER PACK
- 0067-8142 - Ex-lax
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0067-8142). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0067-8142-01 identifies a specific commercial package of 2 blister pack in 1 carton / 12 pill in 1 blister pack of Ex-lax Maximum Strength Stimulant Laxative, a human over the counter drug labeled by Haleon Us Holdings Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 2 billable units per package. This pill is formulated for oral use and contains sennosides as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Haleon Us Holdings Llc on July 01, 2017. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Sennosides are used to treat constipation. They may also be used to clean out the intestines before a bowel examination/surgery. Sennosides are known as stimulant laxatives. They work by keeping water in the intestines, which causes movement of the intestines.
How is this Haleon Us Holdings Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00067814201. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 2 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.